Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/36344
Title: | Response to: ‘Correspondence on ‘Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study’’ by Zheng | Authors: | Abtahi, Shahab Driessen, Johanna H. M. Burden, Andrea M. Souverein, Patrick C. VAN DEN BERGH, Joop van Staa, Tjeerd P. Boonen, Annelies de Vries, Frank |
Issue Date: | 2023 | Publisher: | BMJ PUBLISHING GROUP | Source: | ANNALS OF THE RHEUMATIC DISEASES, 82 (4) (Art. N° e94) | Abstract: | Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'' by Zheng We thank Dr Zheng for his comments on our recently published article in the Annals of the Rheumatic Diseases entitled 'Concom-itant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'. 1 2 Our main goal in this study was to bring more clinical insight into the simultaneous use of these two common medications in patients with rheumatoid arthritis (RA), that is, oral glucocorticoids (GCs) and proton pump inhibitors (PPIs), using data from a large primary care database and pharmacoepidemiological methodologies. Our results showed that there was an interaction in the risk of osteoporotic (OP) fractures with concomitant use of oral GCs and PPIs in patients with RA. Based on the adjusted hazard ratios and according to the formula proposed by Rothman et al, 3 the relative excess risk due to interaction (RERI) was: 1.60-1.23 − 1.22 + 1 = 0.15. We now have also calculated the CIs and the statistical significance of this index using the method proposed by Hosmer and Lemeshow. 4 5 The lower and upper limits of the 95% CI of the RERI were −0.16 and 0.45, respectively, and the p value was 0.36. This means, although we observed a 15% more risk of OP fracture with concomitant use of oral GCs and PPIs in addition to the single use of each drug versus non-use of both, this additive interaction was not statistically significant. As we discussed in our paper, there is currently no proven biological mechanism for an action of PPIs on bone or falling, 6 while the effects of GCs on bone and the musculoskeletal system are quite established. Our secondary analyses (ie, lower fracture risk with long-term or higher daily doses of PPIs compared with short-term or lower daily doses) did not support the few proposed potential mechanisms, such as hypochlorhydria and calcium malabsorption, or an increased fall risk due to malab-sorption of magnesium or vitamin B 12. This is important to consider when interpreting a potential additive interaction between oral GCs and PPIs on fracture risk. Without this basic knowledge, it would be extremely difficult to confer any conclusions on a plausible synergistic action of these two drugs, since it would sound more as a methodological reasoning rather than a clinical explanation. | Notes: | de Vries, F (corresponding author), Maastricht Univ, Med Ctr, Dept Clin Pharm & Toxicol, Maastricht, Netherlands.; de Vries, F (corresponding author), Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands.; de Vries, F (corresponding author), Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands.; de Vries, F (corresponding author), Southampton Gen Hosp, MRC Epidemiol Lifecourse Unit, Southampton, Hants, England. f.devries@uu.nl |
Keywords: | glucocorticoids;rheumatoid arthritis;osteoporosis;epidemiology | Document URI: | http://hdl.handle.net/1942/36344 | ISSN: | 0003-4967 | e-ISSN: | 1468-2060 | DOI: | 10.1136/annrheumdis-2021-219856 | ISI #: | 000726533900001 | Rights: | Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2022 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Response to_ ‘Correspondence on ‘Concomitant use of oral glucocorticoids and proton pump inhibitors and risk.pdf Restricted Access | Published version | 246.56 kB | Adobe PDF | View/Open Request a copy |
WEB OF SCIENCETM
Citations
1
checked on Oct 6, 2024
Page view(s)
24
checked on Sep 7, 2022
Download(s)
6
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.